Screening for Gaucher Disease and Acid Sphingomyelinase Deficiency

NCT06258577 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 50

Last updated 2024-04-15

No results posted yet for this study

Summary

High-risk screening for Gaucher disease and Acid Sphingomyelinase Deficiency in patients with splenomegaly and/or thrombocytopenia in Taiwan

Conditions

  • Gaucher Disease

Sponsors & Collaborators

  • Sanofi

    collaborator INDUSTRY
  • Chung-Hsing Wang

    lead OTHER

Principal Investigators

  • Chung-Hsing Wang · China Medical University Hospital

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-05-01
Primary Completion
2028-12-31
Completion
2028-12-31

Countries

  • Taiwan

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06258577 on ClinicalTrials.gov